| Name | Title | Contact Details |
|---|
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome. The HBV program is focused on advancing a new class of potent, oral core inhibitors that have the potential to increase cure rates for chronically infected patients. The microbiome program is developing novel oral live microbial biotherapeutic candidates with Assembly`s fully integrated platform, including a robust process for strain identification and selection, GMP banking and production, and targeted delivery to the lower gastrointestinal tract with the GEMICEL® technology. We pride ourselves on creating a culture and work environment that is scientifically driven, ambitious, and collaborative. We encourage diversity of thought that leads to great innovation and are looking to add to our dynamic team great people who are driven to transform the lives of patients. We believe our Microbiome platform represents a best in class approach to developing biopharmaceutical agents from live biotherapeutic products. ABI-M201, our lead program in mildly to moderately active ulcerative colitis (UC), is currently in a phase 1b clinical trial. This program is part of a broader collaboration we established with Allergan in 2017 for gastrointestinal programs such as UC, Crohn`s disease and Irritable Bowel Syndromes with potential total development and commercial milestones of up to $2.8 billion. Our internal pipeline comprises first in class or best in class live microbial biotherapeutic approaches in areas such as oncology, immune mediated and metabolic disorders, and other areas of high medical need. Assembly is headquartered in Carmel, Indiana, while the R&D headquarters is in South San Francisco. The Company also has a microbiome manufacturing facility in Groton, CT, and offices in China.
Helping all patients feel known and heard when they need it most. Docent Health`s mission is to help health systems build and retain lasting patient relationships. We are combining best practices from other industries to help health systems deliver the vision of customer-centric care by combining cutting edge consumer technology, retail based strategic marketing, and hospitality inspired service excellence with deep provider experience to increase customer lifetime value and grow market share.
Mousera is accelerating medical advancement by bringing 21st century technology into living systems research. We`re currently recruiting in software, machine learning, computer vision, distributed systems, and user experience, while looking for heads of our preclinical and customer organizations. Contact me to find out more.
Driven by a passion for partnership as well as innovation, HOYA has been a partner to Eye Care Professionals for over 75 years, enabling them to give people the greatest gift, the gift of vision. We provide Eye Care Professionals with the lenses, consultation solutions and other services that help them to develop their practice while changing the way people see the world. We see them as visionaries, and everything we do is for them. Founded in Japan in 1941, today, HOYA has a presence in over 80 countries across the globe.
Our revolutionary technology is radically different than any other form of automated medical billing software or revenue cycle management. Unlike a PMS vendor or a clearinghouse, the Encoda BackOffice suite of products enhances and improves existing billing systems and billing service providers’ operations, making them more intelligent. The difference? On average, our customers increase staff productivity by more than 30% and dramatically reduce operating expenses, helping their practices to grow. How do we do this? We apply business intelligence and programming logic tools from the high-tech community to healthcare, and pass those technological advantages on to medical business offices. In adding this advanced technology to our clients’ systems, we create a direct connection between clients and payers, seamlessly integrating the two environments eliminating the need for human intervention.